has served as a consultant for and/or received honoraria outside of the present study as an advisor/consultant for Tricog Health Inc, Lilly USA, Rivus, Cytokinetics, Roche Diagnostics, Sarfez Therapeutics, Edwards Lifesciences, Merck, Bayer, Novo Nordisk, Alleviant, and Axon Therapies
The appetite suppression from GLP-1 therapy is a feature, not a bugit creates a calorie deficit that drives fat loss
[PubMed] [Google Scholar] 55.Curran MWT, Morhart MJ, Olson JL, Hachisuka A, Chan KM
That is an important framing for anyone tempted to treat it as a shortcut: even in the animal work that generates the interest, the compound is one input alongside energy balance, not a replacement for it
Thirty years of preclinical data, a mechanism that makes biological sense, and early human signals that are encouraging this is not a fringe or pseudoscientific compound
Live strains have to survive shelf life and stomach acid